PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh.\', \'Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.\', \'Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan.\', \'College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.\', \'Research Center, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia.\', \'College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh, Saudi Arabia.\', \'School of Nursing, Wollongong University, Wollongong, NSW, Australia.\', \'Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa, Saudi Arabia.\', \'Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh.\', \'Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India.\', \'Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/21645515.2022.2027197
?:hasPublicationType
?:journal
  • Human vaccines & immunotherapeutics
is ?:pmid of
?:pmid
?:pmid
  • 35172687
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35172687>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35172687>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all